INCY Stock Recent News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL).

Incyte said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.

The U.S. Food and Drug Administration on Wednesday approved drugmaker Incyte Corp's treatment for a type of graft-versus-host disease (GvHD).

On Tuesday, Incyte Corporation INCY reported second-quarter revenue of $1.04 billion, up from $954.6 million a year ago, beating the consensus of $1.03 billion.

Incyte Corporation (NASDAQ:INCY ) Q2 2024 Earnings Conference Call July 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Barry Flannelly - General Manager, North America Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Kripa Devarakonda - Truist Securities Paul Jeng - Guggenheim Partners Brian Abrahams - RBC Capital Markets Vikram Purohit - Morgan Stanley David Lebowitz - Citi Eric Schmidt - Cantor Fitzgerald James Shin - Deutsche Bank Jessica Fye - JPMorgan Chase Jay Olson - Oppenheimer & Company Evan Seigerman - BMO Capital Markets Reni Benjamin - Citizens JMP Andrew Berens - Leerink Partners Gavin Clark-Gartner - Evercore ISI Salveen Richter - Goldman Sachs Operator Hello, and welcome to the Incyte

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.